July 30, 2010 – A drug-eluting coronary bifurcation stent received CE mark this week for clinical use in Europe ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
June 11, 2010 – A new drug-eluting stent (DES) was launched this week in the European Union and other CE mark ...
June 11, 2010
June 3, 2010 – Six-month data from the first 45 patients enrolled in the second stage of a trial for a ...
June 03, 2010
May 27, 2010 – One-year data presented this week at EuroPCR in Paris confirms sustained clinical outcomes with ...
May 27, 2010
May 26, 2010 – In the constantly evolving battle for the best coronary stent, Boston Scientific said today it ...
May 26, 2010
May 26, 2010 – The 12-month study results for a drug-eluting stent that uses hundreds of tiny holes, filled with ...
May 26, 2010
May 25, 2010 – The highly anticipated first results of the RESOLUTE All Comers study were presented today during ...
May 25, 2010
May 25, 2010 – A self-expanding, drug-eluting stent (DES) that just gained CE mark clearance in Europe is designed ...
May 25, 2010
May 12, 2010 – A paclitaxel-eluting coronary stent received CE mark approval for a specific indication to treat ...
May 12, 2010
May 10, 2010 – Patients treated with the Zilver PTX drug-eluting peripheral stent maintained clinical improvement ...
May 10, 2010May 7, 2010 – Findings from the SPIRIT IV trial, one of the largest randomized clinical trials comparing two drug ...
May 07, 2010
May 6, 2010 – Patients who can postpone noncardiac surgery for at least six weeks after receiving a coronary ...
May 06, 2010
May 6, 2010 – After entered the Japanese drug-eluting stent market earlier this year, Abbott's Xience V and ...
May 06, 2010
May 3, 2010 – Excellent safety and clinical outcomes were shown in patients ages 70 and older who received a ...
May 03, 2010
Feature | By Stephanie Labelle, senior analyst, Millennium Research Group
In recent years, many medical device companies saw the underserved lower extremity as an opportunity to enter the ...
May 02, 2010© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now